Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor; Pei Ran Ho; Nolan Campbell; Ih Chang; Aaron Deykin; Fiona Forrestal; Nisha Lucas; Bei Yu; Douglas L. Arnold; MS Freedman; Myla D. Goldman; Hans Peter Hartung; EK Havrdová; Douglas Jeffery; Aaron Miller; F Sellebjerg; Diego Cadavid; Dan Mikol; Deborah Steiner; Emmanuel Bartholomé; Marie D'Hooghe; Massimo Pandolfo; Wijmeersch B Van; Virender Bhan; Gregg Blevins; Donald Brunet; Virginia Devonshire; Pierre Duquette; M Freedman; François Grand'Maison; François Jacques; Yves Lapierre; Liesly Lee; Sarah Morrow; Michael Yeung; Michal Dufek; EK Havrdová; Petr Kanovsky; Ivana Stetkarova; Marika Talabova; Jette Frederiksen; Matthias Kant; Thor Petersen; Mads Ravnborg; F Sellebjerg; Laura Airas; Irina Elovaara; Juha Pekka Eralinna; Taneli Sarasoja; Khedr A Al; D Brassat; B Brochet; W Camu; M Debouverie; D Laplaud; Frenay C Lebrun; J Pelletier; P Vermersch; S Vukusi; K Baum; A Berthele; J Faiss; P Flachenecker; R Hohlfeld; M Krumbholz; C Lassek; M Maeurer; S Meuth; T Ziemssen; O Hardiman; C McGuigan; A Achiron; D Karussis; R Bergamaschi; VB Morra; G Comi; S Cottone; L Grimaldi; GL Mancardi; L Massacesi; U Nocentini; M Salvetti; E Scarpini; P Sola; G Tedeschi; M Trojano; Zaffaroni; Jeremy Hobart

doi:10.1016/s1474-4422(18)30069-3

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor^*
, Pei Ran Ho
, Nolan Campbell
, Ih Chang
, Aaron Deykin
, Fiona Forrestal
, Nisha Lucas
, Bei Yu
, Douglas L. Arnold
, MS Freedman
, Myla D. Goldman
, Hans Peter Hartung
, EK Havrdová
, Douglas Jeffery
, Aaron Miller
, F Sellebjerg
, Diego Cadavid
, Dan Mikol
, Deborah Steiner
, Emmanuel Bartholomé

Marie D'Hooghe, Massimo Pandolfo, Wijmeersch B Van, Virender Bhan, Gregg Blevins, Donald Brunet, Virginia Devonshire, Pierre Duquette, M Freedman, François Grand'Maison, François Jacques, Yves Lapierre, Liesly Lee, Sarah Morrow, Michael Yeung, Michal Dufek, EK Havrdová, Petr Kanovsky, Ivana Stetkarova, Marika Talabova, Jette Frederiksen, Matthias Kant, Thor Petersen, Mads Ravnborg, F Sellebjerg, Laura Airas, Irina Elovaara, Juha Pekka Eralinna, Taneli Sarasoja, Khedr A Al, D Brassat, B Brochet, W Camu, M Debouverie, D Laplaud, Frenay C Lebrun, J Pelletier, P Vermersch, S Vukusi, K Baum, A Berthele, J Faiss, P Flachenecker, R Hohlfeld, M Krumbholz, C Lassek, M Maeurer, S Meuth, T Ziemssen, O Hardiman, C McGuigan, A Achiron, D Karussis, R Bergamaschi, VB Morra, G Comi, S Cottone, L Grimaldi, GL Mancardi, L Massacesi, U Nocentini, M Salvetti, E Scarpini, P Sola, G Tedeschi, M Trojano, Zaffaroni, Jeremy Hobart

^*Corresponding author for this work

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	405-415
Number of pages	0
Journal	The Lancet Neurology
Volume	17
Issue number	5
DOIs	https://doi.org/10.1016/s1474-4422(18)30069-3
Publication status	Published - May 2018

Access to Document

10.1016/s1474-4422(18)30069-3

Cite this

Kapoor, R., Ho, P. R., Campbell, N., Chang, I., Deykin, A., Forrestal, F., Lucas, N., Yu, B., Arnold, D. L., Freedman, MS., Goldman, M. D., Hartung, H. P., Havrdová, EK., Jeffery, D., Miller, A., Sellebjerg, F., Cadavid, D., Mikol, D., Steiner, D., ... Hobart, J. (2018). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet Neurology, 17(5), 405-415. https://doi.org/10.1016/s1474-4422(18)30069-3

@article{f74d6e066a46498a94221d743019ec9a,

title = "Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension",

author = "Raju Kapoor and Ho, \{Pei Ran\} and Nolan Campbell and Ih Chang and Aaron Deykin and Fiona Forrestal and Nisha Lucas and Bei Yu and Arnold, \{Douglas L.\} and MS Freedman and Goldman, \{Myla D.\} and Hartung, \{Hans Peter\} and EK Havrdov{\'a} and Douglas Jeffery and Aaron Miller and F Sellebjerg and Diego Cadavid and Dan Mikol and Deborah Steiner and Emmanuel Bartholom{\'e} and Marie D'Hooghe and Massimo Pandolfo and Van, \{Wijmeersch B\} and Virender Bhan and Gregg Blevins and Donald Brunet and Virginia Devonshire and Pierre Duquette and M Freedman and Fran{\c c}ois Grand'Maison and Fran{\c c}ois Jacques and Yves Lapierre and Liesly Lee and Sarah Morrow and Michael Yeung and Michal Dufek and EK Havrdov{\'a} and Petr Kanovsky and Ivana Stetkarova and Marika Talabova and Jette Frederiksen and Matthias Kant and Thor Petersen and Mads Ravnborg and F Sellebjerg and Laura Airas and Irina Elovaara and Eralinna, \{Juha Pekka\} and Taneli Sarasoja and Al, \{Khedr A\} and D Brassat and B Brochet and W Camu and M Debouverie and D Laplaud and Lebrun, \{Frenay C\} and J Pelletier and P Vermersch and S Vukusi and K Baum and A Berthele and J Faiss and P Flachenecker and R Hohlfeld and M Krumbholz and C Lassek and M Maeurer and S Meuth and T Ziemssen and O Hardiman and C McGuigan and A Achiron and D Karussis and R Bergamaschi and VB Morra and G Comi and S Cottone and L Grimaldi and GL Mancardi and L Massacesi and U Nocentini and M Salvetti and E Scarpini and P Sola and G Tedeschi and M Trojano and Zaffaroni and Jeremy Hobart",

year = "2018",

month = may,

doi = "10.1016/s1474-4422(18)30069-3",

language = "English",

volume = "17",

pages = "405--415",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd.",

number = "5",

}

Kapoor, R, Ho, PR, Campbell, N, Chang, I, Deykin, A, Forrestal, F, Lucas, N, Yu, B, Arnold, DL, Freedman, MS, Goldman, MD, Hartung, HP, Havrdová, EK, Jeffery, D, Miller, A, Sellebjerg, F, Cadavid, D, Mikol, D, Steiner, D, Bartholomé, E, D'Hooghe, M, Pandolfo, M, Van, WB, Bhan, V, Blevins, G, Brunet, D, Devonshire, V, Duquette, P, Freedman, M, Grand'Maison, F, Jacques, F, Lapierre, Y, Lee, L, Morrow, S, Yeung, M, Dufek, M, Havrdová, EK, Kanovsky, P, Stetkarova, I, Talabova, M, Frederiksen, J, Kant, M, Petersen, T, Ravnborg, M, Sellebjerg, F, Airas, L, Elovaara, I, Eralinna, JP, Sarasoja, T, Al, KA, Brassat, D, Brochet, B, Camu, W, Debouverie, M, Laplaud, D, Lebrun, FC, Pelletier, J, Vermersch, P, Vukusi, S, Baum, K, Berthele, A, Faiss, J, Flachenecker, P, Hohlfeld, R, Krumbholz, M, Lassek, C, Maeurer, M, Meuth, S, Ziemssen, T, Hardiman, O, McGuigan, C, Achiron, A, Karussis, D, Bergamaschi, R, Morra, VB, Comi, G, Cottone, S, Grimaldi, L, Mancardi, GL, Massacesi, L, Nocentini, U, Salvetti, M, Scarpini, E, Sola, P, Tedeschi, G, Trojano, M, Zaffaroni, & Hobart, J 2018, 'Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension', The Lancet Neurology, vol. 17, no. 5, pp. 405-415. https://doi.org/10.1016/s1474-4422(18)30069-3

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. / Kapoor, Raju; Ho, Pei Ran; Campbell, Nolan et al.
In: The Lancet Neurology, Vol. 17, No. 5, 05.2018, p. 405-415.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

AU - Kapoor, Raju

AU - Ho, Pei Ran

AU - Campbell, Nolan

AU - Chang, Ih

AU - Deykin, Aaron

AU - Forrestal, Fiona

AU - Lucas, Nisha

AU - Yu, Bei

AU - Arnold, Douglas L.

AU - Freedman, MS

AU - Goldman, Myla D.

AU - Hartung, Hans Peter

AU - Havrdová, EK

AU - Jeffery, Douglas

AU - Miller, Aaron

AU - Sellebjerg, F

AU - Cadavid, Diego

AU - Mikol, Dan

AU - Steiner, Deborah

AU - Bartholomé, Emmanuel

AU - D'Hooghe, Marie

AU - Pandolfo, Massimo

AU - Van, Wijmeersch B

AU - Bhan, Virender

AU - Blevins, Gregg

AU - Brunet, Donald

AU - Devonshire, Virginia

AU - Duquette, Pierre

AU - Freedman, M

AU - Grand'Maison, François

AU - Jacques, François

AU - Lapierre, Yves

AU - Lee, Liesly

AU - Morrow, Sarah

AU - Yeung, Michael

AU - Dufek, Michal

AU - Havrdová, EK

AU - Kanovsky, Petr

AU - Stetkarova, Ivana

AU - Talabova, Marika

AU - Frederiksen, Jette

AU - Kant, Matthias

AU - Petersen, Thor

AU - Ravnborg, Mads

AU - Sellebjerg, F

AU - Airas, Laura

AU - Elovaara, Irina

AU - Eralinna, Juha Pekka

AU - Sarasoja, Taneli

AU - Al, Khedr A

AU - Brassat, D

AU - Brochet, B

AU - Camu, W

AU - Debouverie, M

AU - Laplaud, D

AU - Lebrun, Frenay C

AU - Pelletier, J

AU - Vermersch, P

AU - Vukusi, S

AU - Baum, K

AU - Berthele, A

AU - Faiss, J

AU - Flachenecker, P

AU - Hohlfeld, R

AU - Krumbholz, M

AU - Lassek, C

AU - Maeurer, M

AU - Meuth, S

AU - Ziemssen, T

AU - Hardiman, O

AU - McGuigan, C

AU - Achiron, A

AU - Karussis, D

AU - Bergamaschi, R

AU - Morra, VB

AU - Comi, G

AU - Cottone, S

AU - Grimaldi, L

AU - Mancardi, GL

AU - Massacesi, L

AU - Nocentini, U

AU - Salvetti, M

AU - Scarpini, E

AU - Sola, P

AU - Tedeschi, G

AU - Trojano, M

AU - Zaffaroni, null

AU - Hobart, Jeremy

PY - 2018/5

Y1 - 2018/5

U2 - 10.1016/s1474-4422(18)30069-3

DO - 10.1016/s1474-4422(18)30069-3

M3 - Article

SN - 1474-4422

VL - 17

SP - 405

EP - 415

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 5

ER -